BACKGROUND: Sleep complaints are highly prevalent and associated with cardiovascular disease (CVD) morbidity and mortality. This is the first prospective study to report the association between commonly reported sleep symptoms and the development of the metabolic syndrome, a key CVD risk factor. METHODS: Participants were from the community-based Heart Strategies Concentrating on Risk Evaluation study. The sample was comprised of 812 participants (36% African American; 67% female) who were free of metabolic syndrome at baseline, had completed a baseline sleep questionnaire, and had metabolic syndrome evaluated 3 years after baseline. Apnea-hypopnea index (AHI) was measured cross-sectionally using a portable monitor in a subset of 290 participants. Logistic regression examined the risk of developing metabolic syndrome and its components according to individual sleep symptoms and insomnia syndrome. RESULTS: Specific symptoms of insomnia (difficulty falling asleep [DFA] and "unrefreshing" sleep), but not a syndromal definition of insomnia, were significant predictors of the development of metabolic syndrome. Loud snoring more than doubled the risk of developing the metabolic syndrome and also predicted specific metabolic abnormalities (hyperglycemia and low high-density lipoprotein cholesterol). With further adjustment for AHI or the number of metabolic abnormalities at baseline, loud snoring remained a significant predictor of metabolic syndrome, whereas DFA and unrefreshing sleep were reduced to marginal significance. CONCLUSION: Difficulty falling asleep, unrefreshing sleep, and, particularly, loud snoring, predicted the development of metabolic syndrome in community adults. Evaluating sleep symptoms can help identify individuals at risk for developing metabolic syndrome.
BACKGROUND: Sleep complaints are highly prevalent and associated with cardiovascular disease (CVD) morbidity and mortality. This is the first prospective study to report the association between commonly reported sleep symptoms and the development of the metabolic syndrome, a key CVD risk factor. METHODS:Participants were from the community-based Heart Strategies Concentrating on Risk Evaluation study. The sample was comprised of 812 participants (36% African American; 67% female) who were free of metabolic syndrome at baseline, had completed a baseline sleep questionnaire, and had metabolic syndrome evaluated 3 years after baseline. Apnea-hypopnea index (AHI) was measured cross-sectionally using a portable monitor in a subset of 290 participants. Logistic regression examined the risk of developing metabolic syndrome and its components according to individual sleep symptoms and insomnia syndrome. RESULTS: Specific symptoms of insomnia (difficulty falling asleep [DFA] and "unrefreshing" sleep), but not a syndromal definition of insomnia, were significant predictors of the development of metabolic syndrome. Loud snoring more than doubled the risk of developing the metabolic syndrome and also predicted specific metabolic abnormalities (hyperglycemia and low high-density lipoprotein cholesterol). With further adjustment for AHI or the number of metabolic abnormalities at baseline, loud snoring remained a significant predictor of metabolic syndrome, whereas DFA and unrefreshing sleep were reduced to marginal significance. CONCLUSION:Difficulty falling asleep, unrefreshing sleep, and, particularly, loud snoring, predicted the development of metabolic syndrome in community adults. Evaluating sleep symptoms can help identify individuals at risk for developing metabolic syndrome.
Authors: Hanna-Maaria Lakka; David E Laaksonen; Timo A Lakka; Leo K Niskanen; Esko Kumpusalo; Jaakko Tuomilehto; Jukka T Salonen Journal: JAMA Date: 2002-12-04 Impact factor: 56.272
Authors: Najib T Ayas; David P White; Wael K Al-Delaimy; JoAnn E Manson; Meir J Stampfer; Frank E Speizer; Sanjay Patel; Frank B Hu Journal: Diabetes Care Date: 2003-02 Impact factor: 19.112
Authors: Mary Amanda Dew; Carolyn C Hoch; Daniel J Buysse; Timothy H Monk; Amy E Begley; Patricia R Houck; Martica Hall; David J Kupfer; Charles F Reynolds Journal: Psychosom Med Date: 2003 Jan-Feb Impact factor: 4.312
Authors: George T O'Connor; Brian Caffo; Anne B Newman; Stuart F Quan; David M Rapoport; Susan Redline; Helaine E Resnick; Jonathan Samet; Eyal Shahar Journal: Am J Respir Crit Care Med Date: 2009-03-05 Impact factor: 21.405
Authors: Patricia M Wong; Brant P Hasler; Thomas W Kamarck; Matthew F Muldoon; Stephen B Manuck Journal: J Clin Endocrinol Metab Date: 2015-11-18 Impact factor: 5.958
Authors: Yanping Li; Xuehong Zhang; John W Winkelman; Susan Redline; Frank B Hu; Meir Stampfer; Jing Ma; Xiang Gao Journal: Circulation Date: 2013-11-13 Impact factor: 29.690
Authors: Tibor Fülöp; DeMarc A Hickson; Sharon B Wyatt; Rajesh Bhagat; Michael Rack; Otis Gowdy; Michael F Flessner; Herman A Taylor Journal: Sleep Med Date: 2012-07-25 Impact factor: 3.492
Authors: Wendy M Troxel; Ann Haas; Bonnie Ghosh-Dastidar; Andrea S Richardson; Lauren Hale; Daniel J Buysse; Matthew P Buman; Jonathan Kurka; Tamara Dubowitz Journal: Behav Sleep Med Date: 2019-09-23 Impact factor: 2.964